| Screening | Baseline | Allocation | Post intervention | 6-week follow-up | |||
---|---|---|---|---|---|---|---|---|
Timepoint (week) | − 12 | 0 | 1 | 7 | 13 | |||
Enrolment: | ||||||||
 Eligibility screening | X |  |  |  |  | |||
 Informed consent | X | X |  |  |  | |||
 Allocation |  |  | X |  |  | |||
Interventions: | ||||||||
 CBT-I |  | X | X | X | X | |||
 Waitlist control (WLC) |  | X | X | X | X | |||
Assessments: | ||||||||
 Primary outcome measures |  | CBT-I | WLC |  | CBT-I | WLC | CBT-I | WLC |
  Depression severity (CES-D) |  | X | X |  | X | X | X | X |
  Insomnia severity (ISI) |  | X | X |  | X | X | X | X |
  Sleep quality (PSQI) |  | X | X |  | X | X | X | X |
 Secondary outcome measures |  | CBT-I | WLC |  | CBT-I | WLC | CBT-I | WLC |
  Subjective health (SF-12 Version 1) |  | X | X |  | X | X | X | X |
  Anxiety (HADS-A) |  | X | X |  | X | X | X | X |
  Treatment expectancy (modified CEQ) |  | X | X |  | X |  |  | X |
  Treatment acceptability (modified PARS) |  | X | X |  | X |  |  | X |
  Demographics | X |  |  |  |  |  |  |  |
  Clinical comorbidity | X |  |  |  |  |  |  |  |
 Post-screening eligibility assessments |  | CBT-I | WLC |  | CBT-I | WLC | CBT-I | WLC |
  Withdrawal criteria |  |  |  |  | X | X | X | X |
  Cross-condition contamination check |  |  |  |  |  | X |  | X |